Related Experiment Video
Updated: Aug 17, 2026

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
Opposing central and peripheral effects of atropine on parasympathetic cardiac control
Abstract:
Cardiac vagal efferent (CVE) activity was recorded from fine strands of the cervical vagus of chloralose-urethane-anesthetized dogs weighing an average of 14.6 kg. In spontaneously breathing animals atropine sulfate in doses of 0.003-1.5 mg significantly increased CVE activity even when the activity was corrected for changes in blood pressure. A 50% average increase (P less than 0.001) in mean activity was observed at a dose of 0.15 mg. The increase was not abolished by vagotomy as long as the animals were allowed to breathe spontaneously. The peripheral effect of atropine was characterized by the relationship between CVE activity and measured heart period changes. A 50% peripheral blockade was achieved at a dose of 0.06 mg; a dose of 1.0 mg produced essentially complete (greater than 90%) blockade. The results quantitatively demonstrate that atropine exerts a powerful central stimulating effect on CVE activity while simultaneously blocking vagal heart rate effects at the periphery.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Drugs Acting on Autonomic Ganglia: Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

